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SUMMARY
Research undertaken over the past 40 years has established
many of the general principals concerning immunity to tae-
niid cestodes. Although much is well understood about the
host-protective mechanisms against taeniids and this knowl-
edge has been exploited in studies on vaccine development,
many aspects require further investigation or confirmation.
Some phenomena have come to be regarded as being well
established, while careful analysis of the published data
would suggest that they may be better regarded as hypothe-
ses rather than established facts. This review considers one
selected issue pertaining to immunity to cestode infections
and examines carefully the nature of the evidence that is
available to support conclusions that have been made in this
area. The issue examined is the use of Taenia crassiceps as
a model for cysticercosis in pigs caused by Taenia solium,
together with the S3Pvac vaccine, which has been developed
based on this model. Strong evidence is found to support the
conclusion that defined T. crassiceps antigens can limit
intraperitoneal proliferation of the ORF strain of T. crassi-
ceps in mice; however, the potential for these antigens to
affect T. solium infection in pigs requires further confirma-
tion.
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INTRODUCTION
Taeniid cestodes are unusual parasites in that they seem to
have an Achilles’ heel in relation to their susceptibility to
host immune attack. Intermediate hosts of many taeniid
cestode parasite species have been shown to develop
immune responses following an initial infection that act to
prevent the establishment of parasites from a subsequent
challenge infection while not affecting the parasites estab-
lishing from the initial exposure. This type of immunity,
sometimes referred to as concomitant immunity, acts on
the infective parasite stage, the oncosphere or early post-
oncospheral stages (1). The existence of this Achilles’ heel
has been exploited in the development of a series of highly
effective recombinant vaccines based on oncosphere anti-
gens (2). However, oncospheres are not the only life cycle
stage that can be shown to be a source of host-protective
antigens in taeniid cestodes (3). Also, there is clear evi-
dence for antigenic cross-reactivity, with antigens from one
species being capable of inducing host-protective responses
against a related taeniid species [see, for example (4)].
These characteristics of the taeniid cestode parasites have
encouraged some researchers to investigate host-protective
antigens from sources other than oncospheres and to
source protective antigens for practical use from model
parasite species. One such research effort has involved the
use of Taenia crassiceps in mice as a model for develop-
ment of a vaccine against Taenia solium.
A recent review identified a number of topics concern-
ing immunity to taeniid cestode parasites where, despite
substantial data have been published in the area, either
the issues remained unclear or commonly held interpreta-
tions were not clearly supported by published evidence (1).
The usefulness of T. crassiceps as a model for T. solium
and the S3Pvac vaccine developed using this model was
one area identified as worthy of careful analysis. This
forms the topic of the following review.
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experiments as a source of antigens and as a model for
immunological studies concerning immunity to cysticerco-
sis. Much of this work has been undertaken at the Institu-
to de Investigaciones Biom dicas, Universidad Nacional
Aut noma de M xico, where T. crassiceps has been used
as a model for T. solium infection in pigs. The work has
led to the development of a synthetic peptide vaccine for
T. solium based on epitopes selected from T. crassiceps
proteins (5,6). From information contained in the various
publications, this vaccine, termed S3Pvac, protects mice
against infection with T. crassiceps and can be delivered as
an effective vaccine as a synthetic peptide or via a novel
bacterial vector or in transgenic plant tissue extracts or
via expression on recombinant bacteriophage. When deliv-
ered in extracts from a recombinant bacterial vector, the
vaccine is effective when given orally as well as parenter-
ally. The vaccine also cross-protects pigs against infection
with T. solium and has a therapeutic effect on parasites in
infected pigs causing them to succumb to host inflamma-
tory responses. In addition, the vaccine protects against
infection with the adult tapeworm stage of T. solium in a
laboratory model of infection. These attributes seem likely
to qualify S3Pvac as the most robust of all vaccines in the
field of parasitology, and possibly more broadly. Develop-
ment of the S3Pvac vaccine has been reviewed elsewhere
(5–7). The purpose of the following discussion is to exam-
ine the strength of the data provided in support of the
reported effects of the S3Pvac vaccine and to consider
T. crassiceps as a model parasite for studies on immunity
to cysticercosis.
Prior to commenting on the use of T. crassiceps as a
model for T. solium and the S3Pvac vaccine, it is impor-
tant to point out what could be regarded as a conflict of
interest. The author’s laboratory is engaged in research
that seeks to achieve a similar outcome to the research
being discussed, i.e. the development of a vaccine against
T. solium infection in pigs. The discussion below concen-
trates on aspects relating directly to vaccination, that is
protection in vivo against a parasite challenge. It does not
consider data derived from various in vitro immunological
investigations or antigen characterizations.
TAENIA CRASSICEPS AS A MODEL FOR
TAENIA SOLIUM
Taenia crassiceps is a natural parasite of rodents and is
transmitted by canines as definitive hosts. In the intermedi-
ate host, the parasite develops as a cysticercus in the
abdominal cavity, where it proliferates. An animal infected
with a single egg can potentially develop a heavy burden of
cysticerci through proliferation of the parasite in the perito-
neum. Few taeniid parasites have a similar biology in their
intermediate hosts. The parasite’s site of election in the
intermediate host is similar to T. pisiformis in rabbits and
T. hydatigena in sheep but not to T. solium that predomi-
nantly encysts in the striated muscles of pigs and does not
proliferate. The biology of T. solium seems to be more simi-
lar to T. ovis in sheep and T. saginata in cattle, or even
T. taeniaeformis in rodents, than it is to T. crassiceps.P h y -
logenetic studies based on a variety of comparative assess-
ment criteria place T. ovis and T. saginata close to T. solium
and have T. crassiceps as a more distant relative (8–10).
The particular strain of T. crassiceps that has been used
as a model for T. solium is the ORF strain. T. crassiceps
was originally isolated from a fox and has been main-
tained for some 60 years by direct intraperitoneal passage
of parasites between mice (11). After a number of years of
passage, it was noticed that a particular line of parasites
was growing more quickly in the mice and this rapidly
growing parasite was designated the ORF strain (12). Bio-
logical investigations into this strain have uncovered some
interesting characteristics in comparison the wild-type par-
asite. It can no longer infect the definitive host, has bio-
chemical and immunological differences with the wild-type
parasite (11,13) and is aneuploid (14), having lost one pair
of chromosomes during the years of direct mouse-to-
mouse passage. It is possible that parasite defence mecha-
nisms against host immunological attack were lost along
with the two chromosomes. This may limit the applicabil-
ity of the ORF strain of T. crassiceps as a model for
immunological studies of immunity to cysticercosis.
T. crassiceps is an attractive laboratory model because it
infects mice and can be maintained without recourse to
passage through the definitive host.
VACCINATION WITH TAENIA CRASSICEPS
PARASITE EXTRACTS
Antigenic cross-reactivity among taeniid cestodes is a
widely recognized phenomenon. Antigenic preparations
made from many species can be used as a source of host-
protective antigens against a challenge infection with a
heterologous species (15) or as a source of antigens for
diagnosis of infection with a heterologous cestode (16).
Consistent with this general observation, antigens
obtained directly from T. crassiceps can be used as a
source of material for detection of antibodies raised by
infection with T. solium (17), and partial protection can be
achieved against T. solium infection in pigs using antigens
obtained from T. crassiceps (18) or vice versa (19).
Investigations utilizing T. crassiceps as a model and
source of host-protective antigens for use against T. solium
infection in pigs have followed a general path where
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against an intraperitoneal infection with T. crassiceps and,
having obtained encouraging data in the mouse model,
similar experiments were undertaken in pigs against an
experimental challenge infection with T. solium.
In 1990, Sciutto et al. (19) showed that extracts from
T. solium cysticerci could limit the proliferation of the
ORF strain of T. crassiceps in mice and concluded that
T. crassiceps was a convenient laboratory model in which
to test promising T. solium antigens for vaccine develop-
ment. Valdez et al. (20) sought to fractionate T. crassiceps
antigen extracts to identify individual protective antigens.
They identified SDS–PAGE fractions comprising antigens
of 56, 66 and 74 kDa, which, when used together as a vac-
cine, limited the proliferation of the ORF strain of
T. crassiceps in vaccinated mice, achieving a 74% reduction
in cysticerci numbers in comparison to nonimmunized
controls. Interestingly, the authors noted one antigen frac-
tion that induced statistically greater level of infection
compared to controls.
Subsequently, Sciutto et al. (18) vaccinated pigs with a
total extract of T. crassiceps cysticerci and challenged
them with T. solium. Statistically significantly fewer cysti-
cerci (58% reduction) of T. solium were found developing
in muscle tissues compared to adjuvant-only (Freund’s
Complete Adjuvant) controls; also, controls had more via-
ble parasites (99%) than vaccinates (88%) (18). Vaccination
with the same antigen preparation using alum as adjuvant
led to a statistically significant increase in the number of
cysticerci in the pigs. Pigs vaccinated with T. crassiceps
extract using alum adjuvant had 37% cysticerci that were
damaged, while the control group had 15Æ9% damaged
parasites, suggesting that the effect on cyst viability that
was noted when Freund’s Complete Adjuvant was used
was either adjuvant-specific or not a reliable effect. With
data from a single experiment and where another vacci-
nated group showed no protection, it is difficult to form a
reliable conclusion about the ability of T. crassiceps cysti-
cercus extract to protect pigs against T. solium infection.
Huerta et al. (21) provide further information on the
use of T. crassiceps antigens in pigs. A vaccine trial using
T. crassiceps cysticercus extract was carried out in rustic
pigs, being animals sourced from rural areas rather than
from a large commercial breeder. Sciutto et al.’s (18) find-
ing that vaccination with T. crassiceps extract led to a
reduction in the number of T. solium cysticerci following a
challenge infection was not replicated. However, Huerta
et al. (21) did present evidence to suggest that there was
an effect of vaccination on the degree of inflammation
seen in vaccinated pigs compared to controls, supporting
the conclusions made by Sciutto et al. (18) that the vac-
cine increased the amount of inflammation around cysts.
Huerta et al. (21) vaccinated pigs at either 40 or 70 days
of age and necropsied them 80 days after challenge infec-
tion (110 days after first vaccination). Data were collected
histologically on 694 parasites concerning the degree to
which there was inflammation associated with each para-
site, according to a five-point scale. The paper indicates
that there was statistically significantly more inflammation
in the parasites examined from vaccinated animals com-
pared with controls; however, it is not possible to confirm
the conclusion because the paper does not indicate how
many parasites were examined from each animal, only the
total number examined. Whether those that were exam-
ined were a statistically representative sample cannot be
judged. Taken together, further investigations would be
required to confirm whether T. crassiceps extracts have an
ability to reduce either the number or viability of T. solium
cysticerci in vaccinated pigs.
Manoutcharian et al. (22) refer to the results of an
experiment where pigs were vaccinated with SDS–PAGE
gel cut-outs containing the 56, 66 and 74 kDa antigens of
T. crassiceps, in a similar fashion to the trials that had
previously been conducted in mice (20). Full details of the
experiment were provided in a subsequent paper (23).
Seven pigs were vaccinated with the gel cut-outs. Of the
seven vaccinated animals, only one animal had a single
parasite. By comparison, seven control animals were
infected with 3–7 parasites. The parasite burdens in this
experiment were low; however, the differences between the
groups are statistically significant, and the experiment
does suggest that the gel slices containing T. crassiceps
antigens may have a protective effect in pigs against infec-
tion with T. solium.
In the experiment discussed earlier in which pigs were
vaccinated with gel cut-outs containing various fractions
from a parasite extract, the control animals were immu-
nized with adjuvant alone rather than gel cut-outs con-
taining no antigen. The authors indicate that this was
performed ‘considering previous observations that acryl-
amide does not modify the number of parasites recovered
after infection’. What previous observations the authors
were referring to is unclear as there appears to be no other
publication where pigs had been vaccinated with polyacryl-
amide and subsequently challenged with T. solium. Similar
experiments in mice (20) used nonimmunized animals as
controls.
T H EI M P O R T A N C EO FE X P E R I M E N T A L
CONTROLS
In the publications discussed earlier and in a number of
others discussed later, control groups were either untreated
or given saline or adjuvant alone. A number of experiments
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stances while excluding the specific antigenic preparation
being investigated. This does not detract from conclusions
about the effects of the vaccination per se; however, it does
raise doubts about confidence that observed effects are
directly related to the antigen being tested and are not
nonspecific. A number of situations have been described
where statistically significant, nonspecific protection has
been observed against cysticercosis in mice, for example
following the injection of control DNA samples (24) or
bacterial extracts (25) or plant extracts (26); nonspecific
effects have achieved statistically significant levels of pro-
tection as high as 87%. Similar nonspecific protection has
been obtained with another cestode parasite (27). It may
seem unlikely that preparations such as synthetic peptides
or polyacrylamide gel extracts would provide nonspecific
protection against either T. crassiceps in mice of T. solium
in pigs; however, this possibility remains in the absence of
data to the contrary. Controls of this type do not need to
be included in situations where previous experiments have
included the appropriate controls for nonspecific effects,
establishing clearly the vaccine’s efficacy and specificity.
However, it is important that, at least in initial experi-
ments, appropriate control preparations are included so
that the effects can be clearly demonstrated to relate to
the antigen being tested and are not nonspecific. This is
particularly important where the effects of vaccination are
modest and potentially within the bounds of known non-
specific effects within this group of parasites.
VACCINATION WITH RECOMBINANT
ANTIGENS
Manoutcharian et al. (22) provide the first mention of
cDNA cloning of proteins from T. crassiceps and vaccina-
tion of mice with different recombinant antigens desig-
nated KET; a later paper provided full details (23). A
T. crassiceps cDNA library was screened for clones
expressing antigens recognized by antisera raised against
the 56 and 74 kDa antigens of T. crassiceps cysticerci.
Positive clones were subsequently rescreened for reactivity
with sera from pigs infected with T. solium. Five clones
were found to be positive with the pig sera, and these were
designated KETc1, KETc4, KETc7, KETc11 and KETc12.
The DNA sequence of KETc7 was determined. The other
clones were found to have cDNA inserts ranging from 0Æ4
to 1Æ4 kb. Sequencing of the 3¢ approximately 400 bp of
each cDNA suggested that the inserts were unrelated,
although antibody affinity purified with the clones indi-
cated that some clones showed immunological cross-reac-
tivity. Crude lysates of the clones were used to vaccinate,
mice and KETc1, KETc4, KETc7 and KETc11 were all
shown to significantly reduce the proliferation of cysticerci
of the ORF strain of T. crassiceps compared to controls.
KETc11 significantly increased the level of parasite prolif-
eration in the vaccinated animals.
Rosas et al. (28) cloned the fragment encoding the
KETc7 protein into a DNA vaccine vector and used this
to vaccinate mice. The results of the vaccine trial work are
difficult to decipher in some respects, with the paper refer-
ring to the use of 10 mice per vaccine group, or elsewhere
8 per group, while referring to the results of one group
and indicating that there were only 5 animals in the group.
The vaccine did not induce a statistically significant reduc-
tion in T. crassiceps compared to controls receiving
pcDNA3 DNA. The authors refer to a significant reduc-
tion in the proliferation of the ORF strain of T. crassiceps
in mice receiving the KETc7 DNA vaccine construct com-
pared with the results of mice treated with saline alone. In
a subsequent paper, Cruz-Revilla et al. (29) obtained simi-
lar results. Vaccination of mice with a DNA vaccine
expressing the KETc7 protein did not induce a statistically
significant reduction in parasites in comparison with
pcDNA3-treated controls. The authors indicate that there
was a statistically significant difference if they compared
the KETc7 group with saline-treated controls.
VACCINATION WITH SELECTED ANTIGENIC
EPITOPES
A computer-based epitope prediction software was used to
predict antigenic regions of the KETc7 protein, and three
of these were prepared as synthetic proteins and desig-
nated GK-1, GK-2 and GK-3 (30). These peptides were
shown to react with antibodies in the sera of mice infected
with T. crassiceps and, although Gevorkian et al. (30) refer
to the peptides having reactivity with some sera from
human cases of neurocysticercosis, it is unclear whether
there is a significant difference between the levels shown
and those seen with control sera. The peptides did not
react with sera from pigs infected with T. solium. A fol-
low-up paper (31) provides the results of a vaccination
experiment in mice against a challenge infection with
T. crassiceps involving each of the three peptides, together
with a second trial using GK-1 only. In both trials, mice
vaccinated with 50 lg of GK-1 had fewer cysticerci than
mice immunized with adjuvant only. The authors indicate
that they believed GK-2 and GK-3 provided no protec-
tion. In this case, the GK-2 and GK-3 groups could possi-
bly act as ‘irrelevant’ peptide controls for comparison with
the results of GK-1 (rather than using the adjuvant-only
controls). However, mice vaccinated with GK-2 or GK-3
also developed fewer cysticerci than controls and t-test
comparisons of parasite numbers in the groups vaccinated
M. W. Lightowlers Parasite Immunology
704   2010 Blackwell Publishing Ltd, Parasite Immunology, 32, 701–709with GK-2 or GK-3, and those vaccinated with GK-1
show no significant differences. A second vaccination trial
using GK-1 as either free peptide or conjugated to carrier
proteins provided further support to the potential protec-
tive efficacy of the GK-1 peptide; however, control mice
were immunized with adjuvant alone (saponin on this
occasion).
Toledo et al. (32) extended the work on computer-
predicted antigenic epitopes of the KET proteins. One
epitope was predicted from the protein sequence of KETc1
and one also from KETc12. With the exception of the
paper by Huerta et al. (33), the research group’s subsequent
publications use the nomenclature KETc1 and KETc12 to
refer to these 12 and 8 amino acid peptides, respectively,
rather than the recombinant antigens originally given the
same designations by Manoutcharian et al. (23). Three
vaccine trials were conducted in mice using each of the
KETc1 or KETc12 peptides against a challenge infection
with T. crassiceps. In each case, a statistically significant
reduction was observed in mice vaccinated with KETc1
(67–89% reduction) and KETc12 (57–70% reduction).
Control mice did not receive an irrelevant peptide. Protec-
tion with the KETc1 peptide was confirmed by Sciutto
et al. (25) in another trial in mice. While it is clear that the
KETc1, KETc12 and GK-1 peptide preparations induce a
significant reduction in T. crassiceps infection in mice, the
specificity of those reductions in relation to the KET and
GK-1 peptides has not been demonstrated clearly.
A novel expression system was evaluated for the deliv-
ery of the KETc1 peptide. The group describes the crea-
tion of a Brucella spp vector in which peptide epitopes
can be expressed as part of the bacterial lumazine syn-
thase protein (25,34). This protein assembles into stable
dimers of pentamers, potentially providing an excellent
epitope delivery system. The 12 amino acid peptide
KETc1 was cloned into the vector, and mice were immu-
nized with either the nonrecombinant bacterial lumazine
synthase, lumazine synthase incorporating the KETc1 pep-
tide, peptide alone or nonimmunized. Immunization with
KETc1 peptide induced a statistically significant reduction
in the proliferation of the ORF strain of T. crassiceps in
vaccinated mice in comparison to nonimmunized controls.
Mice immunized with the lumazine synthase incorporating
KETc1 also developed significantly fewer cysticerci com-
pared with the unimmunized controls. Mice immunized
with the nonrecombinant lumazine synthase revealed a
significant nonspecific reduction in number of cysticerci
(57% reduction). Comparison between mice immunized
with lumazine synthase and those immunized with lum-
azine synthase incorporating the KETc1 peptide revealed
a reduced number in those receiving the construct incor-
porating the KETc1 peptide (P =0 Æ034, t-test; P =0 Æ082;
Mann–Whitney U-test; P =0 Æ131, Tukey t-test). Rosas
et al. (34) undertook follow-up experiments, which con-
firmed both the nonspecific protection with wild-type lum-
azine synthase and also an additional level of protection
with lumazine synthase incorporating KETc1. Data in
these two papers support the conclusion that the KETc1
peptide expressed with lumazine synthase can induce pro-
tection against T. crassiceps infection in mice specifically
associated with the KETc1 peptide component.
Huerta et al. (33) undertook a vaccination trial in pigs
using a combination of KETc1, KETc12 and CK-1 pep-
tides against infection with T. solium. The trial was under-
taken in the field against a natural challenge infection.
The peptide combination used here has been referred to in
some subsequent publications as S3Pvac (synthetic three
peptide vaccine). Huerta et al. (33) adopted a strategy
designed to take account of the potentially heterogeneous
distribution in risk of exposure of the different experimen-
tal animals (35–37). A total of 140 control pigs and 138
vaccinated pigs were distributed in pairs amongst 70 dif-
ferent households. Vaccinated pigs received two immuniza-
tions with the three peptides plus saponin adjuvant at 60
and 90 days of age. Control pigs received saponin alone.
Pigs were subjected to examination at necropsy between
10 and 12 months of age. At the completion of the trial,
18 vaccinated and 20 control pigs had died from causes
unrelated to the experiment. Significantly fewer animals
were infected in the vaccinated group (9 of 120) compared
with the control group (19 of 120). Comparison of the
burdens of infection in the two groups revealed a signifi-
cant difference. A larger proportion of cysts in vaccinated
animals were found to be necrotic (41%) compared to the
proportion in controls (3Æ9%); it is not clear whether this
difference was statistically significant. Based on the total
number of parasites in the vaccinated and control groups,
the authors calculated that the vaccine provided a 97Æ9%
reduction in parasites. This conclusion is not supported by
a statistical comparison of cyst numbers in the infected
animals in the two groups (P =0 Æ534, Mann–Whitney
U-test). Four animals in the control group had >10 000
cysts, while the highest number of parasites in a vaccinated
animal was 1286, and this difference accounted for most
of the 97Æ9% difference in total cyst numbers between the
groups. The experimental design involved data pairs (vac-
cinated and control animals distributed in pairs to differ-
ent households). The results were not analysed or
provided as paired data. During the trial, 38 pigs became
unavailable for necropsy; it seems likely that there were
households where one member of a pair was unavailable
at the time the necropsies were performed. The paper does
not provide information about infection levels in the ani-
mals in relation to whether one member or both members
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infected control animals were from households where the
associated vaccinated animal was unavailable for necropsy
cannot be determined.
Two further field trials have been undertaken with
S3Pvac or variations of it. One utilized the same peptides
as those used by Huerta et al. (33) and was undertaken in
the State of Morelos, M xico (38). A total of 381 piglets
were included in the trial, 32 of which were vaccinated
with adjuvant alone, 95 received one injection of the
S3Pvac and 254 received two immunizations with S3Pvac.
At the time the pigs were necropsied, 56% of the experi-
mental animals could not be recovered, leaving 20 con-
trols, 48 in the group receiving one immunization and 98
in the group receiving two immunizations. The proportion
of infected animals (2⁄20, 2⁄48 and 3⁄98, respectively)
suggested a possible positive effect of the vaccine, but sta-
tistical comparisons were not significant. The authors
made statistical comparisons after incorporating addi-
tional data from what were termed ‘sentinel pigs’. These
animals were examined for T. solium infection at times
either before or after the field trial was undertaken. Infor-
mation provided about these animals is limited; it is
unclear whether including these animals as additional con-
trols in the analyses could be supported. However, after
incorporating these animals, comparisons with the vacci-
nated groups revealed statistically significant protection by
the vaccine. In conclusion, the field trials described by
Huerta et al. (33) and Sciutto et al. (38) provide some
evidence to suggest a positive effect of the S3Pvac vaccine
in reducing the level of cysticercosis in vaccinated pigs;
however, they do not provide compelling evidence for this
conclusion.
Noting that a greater proportion of T. solium cysticerci
in S3Pvac-vaccinated pigs were necrotic compared with
controls in the field trial undertaken by Huerta et al. (33),
de Aluja et al. (39) undertook an experiment in pigs to test
the hypothesis that the vaccine had a cysticidal effect.
Groups of five pigs were experimentally infected with
T. solium and, 1 month later, vaccinated with either adju-
vant alone or the CK-1 peptide or S3Pvac. Cysts were
counted and assessed for the level of cyst-associated inflam-
mation 8 months after the experimental infection. The
paper indicates that there was a statistically significant
reduction in the number of cysticerci in the muscles in
S3Pvac-treated pigs vs. the number in controls (total 1039
cysts in controls; 563 in vaccinates) and a significantly
increased percentage of damaged (nonvesicular) cysticerci
in the muscles of S3Pvac-treated pigs compared to controls
(total 61% damaged cysts in controls; 6% in vaccinates). de
Aluja et al. (39) do not provide information about their sta-
tistical methods; examination of the data in the paper by
Mann–Whitney U-test finds no statistically significant dif-
ference between S3Pvac-immunized pigs and controls with
respect to either the total number of cysticerci or the per-
centage of damaged cysticerci. de Aluja et al. (39) include
data obtained in in vitro measures of cyst viability on what
were described as a ‘representative sample’ of cysticerci
from the muscles, and these data supported the authors’
conclusion that the S3Pvac had a therapeutic effect on
T. solium cysticercosis in vaccinated pigs. No information is
provided about what was meant by the term ‘representative
sample’, and data on cysts from individual animals were
not provided. In summary, it is difficult to concur with the
authors’ conclusion that S3Pvac has a (statistically) signifi-
cant therapeutic effect on T. solium infection in pigs, based
on the information provided in the paper.
In an adaptation of the S3Pvac, nucleotide sequences
encoding the peptides comprising S3Pvac (KETc1,
KETc12 and GK-1), as well as the entire KETc7 protein,
were cloned by Manoutcharian et al. (40) into either the
PIII protein or coat protein VIII of the filamentous bacte-
riophage M13. A mixture of phage expressing this antigen
combination was termed CPLV (anti-cysticercotic phage
vaccine). Data are provided about the effect of using this
recombinant phage to vaccinate mice against T. crassiceps
and pigs against T. solium. The results of the vaccine trial
in mice are only given as the total number of cysts in con-
trols given nonrecombinant phage (990 cysts) and the total
number in vaccinates (338 cysts). This difference was indi-
cated as ‘significant’ although what this indicates is
unclear. The phage vaccine was tested in three pigs given
the phage subcutaneously, three given the phage orally
and five controls injected subcutaneously with nonrecom-
binant phage. All three pigs vaccinated with phage
expressing the KET antigens had low numbers of T. solium
cysticerci after the challenge infection (range 0–36) com-
pared to the controls (range 91–580). Those receiving
the phage orally showed a mixed response in terms of the
number of parasites (31, 53 and 474 cysticerci). The
authors noted that in three of the five infected animals
that received the recombinant phage either subcutaneously
or orally and were infected with cysticerci (one animal had
no cysts), the majority of the cysticerci were necrotic.
When data from the pigs receiving recombinant phage
orally and subcutaneously were combined and compared
with the controls, the percentage of necrotic cysticerci in
the vaccinated group(s) was statistically significantly
greater than that in the controls. The trial did not include
a sufficient number of pigs in the vaccine groups to allow
a confident conclusion to be drawn about the possible
effects on either cyst numbers or cyst viability, although
taken as preliminary data they could be considered
encouraging in these respects.
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ogy for the production of the KETc1, KETc12 and GK-1
peptides to the methods used in the previous studies. Oli-
gonucleotides encoding these peptides were cloned into an
embryonic cell line of the papaya plant. Extracts were pre-
pared from recombinant plant callus tissue derived from a
number of different clones expressing each of the peptides
individually and the material used to vaccinate mice
against a challenge infection with T. crassiceps.I nt w oo f
the three experiments described, control mice immunized
with extracts from nonrecombinant plants showed a statis-
tically significant reduction in the number of cysticerci fol-
lowing the challenge infection compared with
unimmunized controls (68% reduction and 80% reduction
in the two experiments, respectively). Comparisons
between the results obtained with one KETc7 clone and
with several clones expressing KETc1 or KETc12 showed
statistically significantly reduced numbers of T. crassiceps
following the challenge infection compared with mice
immunized with the extracts from the nonrecombinant
plants. Several of the groups vaccinated with the extracts
incorporating the KET peptides had the majority of the
vaccinated animals completely free of parasites. Two
groups immunized with extracts from clones expressing
the KETc12 peptide had 98% fewer parasites than the
mice injected with the nonrecombinant plant extract. It
would appear that the KET peptides delivered in this way
are superior to the synthetic peptides in inducing protec-
tion against T. crassiceps in mice. It is noteworthy that up
to 80% nonspecific protection is seen in mice vaccinated
with nonrecombinant plant extract. Nevertheless, the levels
of cyst reduction seen in mice vaccinated with the KET
peptides expressed in the plant extracts were repeatedly
greater than the level of nonspecific reduction seen with
control plant extracts, and hence, there is strong evidence
to support the efficacy of the KETc1 and KETc12 pep-
tides, in particular, in reducing the level of T. crassiceps
proliferation in mice.
The most recent field trial undertaken to assess the
potential for T. crassiceps antigens or epitopes to protect
pigs against T. solium infection was that of Morales et al.
(41) that describes the third in the series of field trials of
the S3Pvac vaccine. The trial was carried out in the State
of Puebla in M xico. The vaccine used was the same mix
of four recombinant bacteriophages that were developed
by Manoutcharian et al. (40).
There is some confusion in the nomenclature being used
for the various vaccines in different papers. Prior to the
publication by Morales et al. (41), all references to
‘S3Pvac’ had been to a combination of three synthetic
peptides (KETc1, KETc12 and CK-1), also being the pep-
tide combination used in the group’s two previous field
trials. Manoutcharian et al. (40) refer to the combination
of the four bacteriophage incorporating KETc1, KETc12
and CK-1 peptides together with the full KETc7 protein,
as CPLV (anti-cysticercotic phage vaccine). However, Mor-
ales et al. (41) use the S3Pvac term to refer to a combina-
tion of bacteriophage, the same combination that
Manoutcharian et al. (40) had earlier referred to as CPLV.
In their field trial, Morales et al. (41) vaccinated half of
each litter of piglets used in the study and half acted as con-
trols. The vaccine comprised a combination of 1 · 10
12 of
each of the four bacteriophage types; control pigs were vac-
cinated with saline. There were 626 vaccinated animals and
421 control animals at the beginning of the trial; necropsy
data were collected from 134 controls and 197 vaccinated
animals examined between 5 and 27 months after the start
of the trial. Vaccination was shown to statistically signifi-
cantly reduce the proportion of infected pigs (6Æ6% in vacci-
nates and 14Æ2% in controls) as well as the number of
cysticerci counted at necropsy (mean number of cysts per
community 8Æ4 cysts in infected vaccinates and 65Æ5 cysts in
controls). These data provide evidence that the vaccine used
in this study can reduce both the prevalence (54%) and
intensity (87%) of T. solium infection in a field situation.
While the data are strong to indicate that the bacteriophage
vaccine provided significant protection against T. solium
infection in this field trial, it is not clear that the effect was
associated with the KET peptide component. Control ani-
mals received an immunization with saline alone. It has not
been established that there is no nonspecific effect on the
susceptibility of pigs to T. solium infection in pigs immu-
nized with 4 · 10
12 bacteriophages. The control animals in
the experiment undertaken by Manoutcharian et al. (40)
did receive an injection with nonrecombinant bacterio-
phage, and all animals became infected with T. solium cysti-
cerci following the challenge infection, but it is not known
whether the number of parasites establishing in these ani-
mals would have been the same in animals not immunized
with the control bacteriophage. As mentioned previously,
substantial nonspecific effects of up to 87% protection have
been described for various control vaccine preparations
when used in mice against T. crassiceps.
Wu et al. (42) have described the creation of a hepatitis
B core protein fusion incorporating the KETc1, KETc12
and GK-1 peptides. The sequence encoding the modified
hepatitis B core protein sequence was cloned into the
pVAX3.0 vector to create a DNA vaccine. This vaccine
was used in pigs against an experimental challenge infec-
tion with T. solium. Control pigs received pVAC3.0 DNA.
Pigs vaccinated with the DNA vaccine expressing the KET
peptides as part of the hepatitis B core protein had statis-
tically significantly fewer cysticerci development following
the T. solium challenge infection compared with control
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cine induced protection against T. solium infection, but the
specificity of this protection in relation to the KET pep-
tides would require confirmation. This is because of the
KET test group received vector expressing hepatitis B core
protein plus KET peptides, while the controls received a
vector not expressing the hepatitis B core protein, and
hence, the experiment was not controlled for potential
nonspecific effects of hepatitis B core protein.
CONCLUSIONS
In summary, the published evidence provides solid support
for the following conclusions about the use of T. crassiceps
antigens as vaccines against T. crassiceps in mice or T.
solium in pigs:
• Native antigens of T. crassiceps and T. solium provide
protection for mice against the proliferation of the ORF
strain of T. crassiceps.
• KETc1, KETc4 and KETc7 recombinant proteins pro-
tect mice against T. crassiceps.
• KETc1 peptide protects mice against T. crassiceps when
delivered as a Brucella lumazine synthase fusion protein.
• KETc1 or KETc12 peptides protect mice against
T. crassiceps when prepared from transgenic papaya tis-
sue.
• A mixture of 4 · 10
12 bacteriophages comprising equal
numbers expressing KETc1, KETc12 and CK-1 peptides
and the KETc7 protein provides protection in pigs
against a natural field infection with T. solium, although
the specificity of this protection relating to the KET
component of the vaccine, rather than the bacteriophage
component, has yet to be established.
Taking into account the analyses outlined earlier, the
available evidence, while not arguing against the following
hypotheses, does not provide solid support for the follow-
ing:
• Protection in pigs against an experimental infection with
T. solium induced using native antigens from T. crassi-
ceps.
• Protective efficacy of KETc7 in mice against T. crassi-
ceps infection when delivered as a DNA vaccine.
• Protective efficacy of KET synthetic peptides in protect-
ing mice against infection with T. crassiceps or protecting
pigs against an experimental infection with T. solium.
• A therapeutic effect of the synthetic peptide vaccine
S3Pvac against T. solium infection in pigs.
• A protective effect of the S3Pvac synthetic peptide vac-
cine against T. solium infection in pigs.
Further research is required using the S3Pvac vaccine to
establish clearly the potential value of the vaccine for use
against T. solium infection in pigs and to confirm that the
effects described for the vaccine delivered as recombinant
bacteriophage are associated with the antigen-specific
component of the vaccine rather than the bacteriophage
vector.
There has been an increase in interest in the potential
for vaccination to play a role in control of T. solium trans-
mission, with a number of research groups having
described effective vaccines for use in pigs (43). It will be
important that these vaccines are validated independently
and that those shown to be reliable and effective are
assessed for other attributes such as cost and ease of use
in practical situations.
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